Skip to content

Kiniksa Pharmaceuticals International, plc

KNSA· Nasdaqxbrl foundCIK 1730430

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · +0.46%
Market cap
$15.13B
157.14M shares
Filings
779
$285.97M
Q3 2026+60.1% FY25 yoy
$47.35M
Q3 2026N/M FY25 yoy
$54.24M
Q3 2026N/M FY25 yoy
$143.94M
Q3 2026derived+436.8% FY25 yoy
$0.56
Q3 2026N/M FY25 yoy
$81.66M
Q3 2026−9.8% FY25 yoy
$15.13B
138.1×
16.0×
21.3×
1.30%
—

Twelve months to Sep 30, 2026 · derived

Price

$96.28+137.42%+$55.73past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$677.56MFY 2025
$677.56M0FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$677,564,000reported
FY 20242024-12-31$423,239,000reported
FY 20232023-12-31$270,259,000reported
FY 20222022-12-31$220,180,000reported
FY 20212021-12-31$38,544,000reported

Capital returns

Dividends and buybacks · FY2017 to FY2018
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2018$0.00—$0.00————
FY2017$0.00—$0.00————

Segments

Products
Revenue by Products, FY2021 to FY2025FY2021Product revenue, net · FY2021 · $38.54MFY2022Product revenue, net · FY2022 · $122.52MLicense and collaboration revenue · FY2022 · $97.66MFY2023Product revenue, net · FY2023 · $233.18MLicense and collaboration revenue · FY2023 · $37.08MFY2024Product revenue, net · FY2024 · $417.03MLicense and collaboration revenue · FY2024 · $6.21MFY2025Product revenue, net · FY2025 · $677.56M
LineFY2025ShareChange
Product revenue, net$677.56M100%+62.5%
License and collaboration revenue———
Total$677.56M

From the 10-K filed Feb 24, 2026KNSA

Pharmaceutical preparations

Kiniksa Pharmaceuticals International, plc is the 46th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Kiniksa Pharmaceuticals International, plc · CIK 1730430 · Engraved from SEC EDGAR